Sales of erectile dysfunction generic drugs are increasing

Last year's erectile dysfunction treatment market sales reached ₩112.4 billion, ↓1.3% from the previous year

Due to COVID-19 pandemic, suffer heavily in the first half of last year

PalPal continues to be number one. Leading sales of generic such as Cendom and Gugu

Sales of the domestic erectile dysfunction treatment market decreased due to COVID-19.

 

Sales declined, mainly for large items in the early days of the COVID-19 spread, and recovered after the second half of the year.

 

Although sales of major products were low, generic products sold by Korean companies such as Hanmi and Chong Kun Dang were launched.

 

According to IQVIA, a drug research institute on the 5th, the domestic erectile dysfunction treatment market last year was ₩11.2 billion, a 1.3% decrease from the previous year.

 

After the expiration of patents for blockbuster drugs such as Viagra and Cialis, generics were released, increasing sales in the erectile dysfunction treatment market.

 

It increased from ₩97.8 billion in 2016 to ₩104.5 billion in 2017, ₩108.2 billion in 2018, and ₩113.9 billion in 2019.

 

However, the size of the market has shrunk in four years after experiencing COVID-19 incident.

 

In the first quarter of last year, the erectile dysfunction treatment market fell 4.8% year-on-year with a joint venture of ₩26.9 billion in sales.

 

In the second quarter, sales rebounded to ₩27.6 billion, which was down 0.4% from the same period last year.

 

In the first half of last year, the number of confirmed cases peaked in Daegu and Gyeongbuk since January 20, last year when the first COVID-19 confirmed in Korea.

 

In the industry, as the fear of unexpected infectious diseases spread rapidly, sales of patients decreased due to fewer visits to hospitals and inability to conduct sales marketing activities.

 

This is because the erectile dysfunction treatment market is less severe than chronic diseases such as high blood pressure and diabetes, and is not an essential drug.

 

The erectile dysfunction treatment market has recovered in earnest since 2H.

 

It rose for 3 consecutive quarters to ₩28.6 billion in the third quarter of last year and ₩29.4 billion in the fourth quarter.

 

Compared to the initial spread of COVID-19, the market for erectile dysfunction treatments also recovered as people's social activities became more active.

 

Even large-sized items that were leading the market could not avoid the aftermath of COVID-19.

 

However, generics sold by domestic companies were less damaged than original products.

 

Hanmi's PalPal sales were ₩21.2 billion last year.

 

Compared to the previous year, sales decreased by 5.3%, accounting for 18.9%.

 

PalPal is a product released immediately after the expiration of the patent for Viagra (Sildenafil) in 2012.

 

After overtaking Viagra in 2013, it has continued to dominate by surpassing the sales of Cialis (Tadalafil) in 2015.

 

Last year's sales of Cendom by Chong Kun Dang, generic for Viagra, fell 1.8% from the previous year to ₩10.2 billion.

 

And it surpassed Viagra and ranked second in sales.

 

Among generic products, Hanmi Pharmaceutical's Gugu was remarkable.

 

Gugu grew 13.6% year-on-year with sales of ₩7.9 billion last year.

 

It is the only product in the top 5 sales in both original and generic sales that has increased its annual sales.

 

Gugu is generic for Cialis.

 

Pfizer Korea's Viagra reduced its annual sales by 11.1% from ₩9.6 billion in 2019 to ₩8.6 billion last year.

 

Based on last year's cumulative sales, Viagra's market share was 7.6%.

 

It fell 3.3 %p in four years from 10.9% in 2016.

 

Cialis' sales last year amounted to ₩6.1 billion.

 

The market share was 5.5%, which was cut in half from 2016 (10.1%).